{"id":58316,"date":"2026-02-27T20:14:23","date_gmt":"2026-02-27T12:14:23","guid":{"rendered":"https:\/\/flcube.com\/?p=58316"},"modified":"2026-02-27T20:14:24","modified_gmt":"2026-02-27T12:14:24","slug":"zai-lab-reports-457m-full-year-revenue-16-growth-driven-by-xacduro-and-nuzyra-expansion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58316","title":{"rendered":"Zai Lab Reports $457M Full\u2011Year Revenue \u2013 16% Growth Driven by Xacduro and Nuzyra Expansion"},"content":{"rendered":"\n<p><strong>Zai Lab (<a href=\"https:\/\/www.google.com\/finance\/quote\/ZLAB:NASDAQ\">NASDAQ:\u202fZLAB<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/9688:HKG\">HKG:\u202f9688<\/a>)<\/strong> announced <strong>Q4 and full\u2011year 2025 financial results<\/strong>, with <strong>net product revenue reaching USD\u202f457.2\u202fmillion<\/strong> (up <strong>16% YoY<\/strong>). The growth was primarily driven by <strong>increased sales volumes<\/strong> of <strong>Xacduro (durlobactam\/sulbactam)<\/strong> and <strong>Nuzyra (omadacycline)<\/strong>, alongside steady performance from the <strong>PARP inhibitor franchise<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance-summary\">Financial Performance Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q4\u202f2025<\/th><th>Full\u2011Year\u202f2025<\/th><th>YoY Growth<\/th><\/tr><\/thead><tbody><tr><td><strong>Net Product Revenue<\/strong><\/td><td>USD\u202f127.1\u202fM<\/td><td>USD\u202f457.2\u202fM<\/td><td><strong>+16%<\/strong> (CER)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-core-product-performance\">Core Product Performance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Q4\u202f2025 ($M)<\/th><th>FY\u202f2025 ($M)<\/th><th>Key Highlights<\/th><\/tr><\/thead><tbody><tr><td><strong>Zejula (niraparib)<\/strong><\/td><td>56.0 (+16%)<\/td><td>189.0<\/td><td>Hospital sales leader among PARP inhibitors for ovarian cancer in China despite competition<\/td><\/tr><tr><td><strong>Vyvgart (efgartigimod)<\/strong><\/td><td>21.9<\/td><td>94.2<\/td><td>Q4 includes USD\u202f5.6M NRDL renewal rebate<\/td><\/tr><tr><td><strong>Xacduro (durlobactam\/sulbactam)<\/strong><\/td><td>10.7 (+225%)<\/td><td>22.9 (+593%)<\/td><td>Rapid growth post Q4\u202f2024 launch<\/td><\/tr><tr><td><strong>Nuzyra (omadacycline)<\/strong><\/td><td>16.0 (+45%)<\/td><td>60.8 (+41%)<\/td><td>Expanded market coverage and penetration<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-2026-strategic-pipeline-milestones\">2026 Strategic Pipeline Milestones<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Class<\/th><th>2026 Milestone<\/th><\/tr><\/thead><tbody><tr><td><strong>Zocilurtatug pelitecan (zoci)<\/strong><\/td><td>DLL3 ADC<\/td><td>3 registrational\/pivotal studies: 2L+ SCLC, 1L SCLC, extrapulmonary NECs<\/td><\/tr><tr><td><strong>ZL\u20111503<\/strong><\/td><td>IL\u201113\/IL\u201131R\u03b1 bispecific<\/td><td>First\u2011in\u2011Human (FIH) Phase 1\/1b data release<\/td><\/tr><tr><td><strong>ZL\u20116201<\/strong><\/td><td>LRRC15 ADC<\/td><td>Global Phase 1 ongoing<\/td><\/tr><tr><td><strong>ZL\u20111222<\/strong><\/td><td>PD\u20111\/IL\u201112 immunocytokine<\/td><td>IND\u2011enabling studies completion<\/td><\/tr><tr><td><strong>ZL\u20111311<\/strong><\/td><td>MUC17 T\u2011cell engager<\/td><td>IND submission targeted<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-priorities\">Strategic Priorities<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oncology Leadership:<\/strong> <strong>DLL3 ADC (zoci)<\/strong> advances to <strong>pivotal studies<\/strong> across small cell lung cancer (SCLC) and neuroendocrine carcinomas, positioning Zai Lab in <strong>high\u2011unmet\u2011need tumor types<\/strong>.<\/li>\n\n\n\n<li><strong>Immunology Expansion:<\/strong> <strong>IL\u201113\/IL\u201131 bispecific<\/strong> targets <strong>atopic dermatitis and pruritus<\/strong>; FIH data will inform differentiation vs. existing IL\u201113\/IL\u201131 programs.<\/li>\n\n\n\n<li><strong>Novel Modalities:<\/strong> Investment in <strong>T\u2011cell engagers<\/strong> and <strong>immunocytokines<\/strong> beyond IL\u201112 diversifies pipeline beyond traditional antibodies and ADCs.<\/li>\n\n\n\n<li><strong>China Commercial Execution:<\/strong> Zejula maintains <strong>PARP inhibitor leadership<\/strong> despite competitive pressure; Xacduro and Nuzyra demonstrate <strong>launch execution capabilities<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>China Biotech Revenue Growth<\/strong><\/td><td>16% growth in challenging pricing environment demonstrates commercial resilience<\/td><\/tr><tr><td><strong>Xacduro Trajectory<\/strong><\/td><td>593% annual growth validates antibiotic demand amid antimicrobial resistance concerns<\/td><\/tr><tr><td><strong>DLL3 ADC Competition<\/strong><\/td><td>Zai Lab joins Amgen, Roche, and others in SCLC TCE\/ADC race; registrational studies critical for first\u2011mover positioning<\/td><\/tr><tr><td><strong>Immunocytokine Innovation<\/strong><\/td><td>PD\u20111\/IL\u201112 fusion represents next\u2011generation immuno\u2011oncology approach; IND\u2011enabling studies progress supports 2027 clinical entry<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding 2026 revenue guidance, pipeline milestone achievement, and clinical data readouts. Actual results may differ due to risks including competitive dynamics, clinical trial enrollment challenges, and reimbursement negotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/Zai-Lab-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Recent-Corporate-Updates.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates.\"><\/object><a id=\"wp-block-file--media-670ac291-e257-450f-8294-228cbcc12712\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/Zai-Lab-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Recent-Corporate-Updates.pdf\">Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/Zai-Lab-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Recent-Corporate-Updates.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-670ac291-e257-450f-8294-228cbcc12712\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Zai Lab (NASDAQ:\u202fZLAB, HKG:\u202f9688) announced Q4 and full\u2011year 2025 financial results, with net product revenue&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,869,4541,413],"class_list":["post-58316","post","type-post","status-publish","format-standard","hentry","category-company","tag-finanical-reports","tag-hkg-9688","tag-nasdaq-zlab-2","tag-zai-lab"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zai Lab Reports $457M Full\u2011Year Revenue \u2013 16% Growth Driven by Xacduro and Nuzyra Expansion - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zai Lab (NASDAQ:\u202fZLAB, HKG:\u202f9688) announced Q4 and full\u2011year 2025 financial results, with net product revenue reaching USD\u202f457.2\u202fmillion (up 16% YoY). The growth was primarily driven by increased sales volumes of Xacduro (durlobactam\/sulbactam) and Nuzyra (omadacycline), alongside steady performance from the PARP inhibitor franchise.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58316\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zai Lab Reports $457M Full\u2011Year Revenue \u2013 16% Growth Driven by Xacduro and Nuzyra Expansion\" \/>\n<meta property=\"og:description\" content=\"Zai Lab (NASDAQ:\u202fZLAB, HKG:\u202f9688) announced Q4 and full\u2011year 2025 financial results, with net product revenue reaching USD\u202f457.2\u202fmillion (up 16% YoY). The growth was primarily driven by increased sales volumes of Xacduro (durlobactam\/sulbactam) and Nuzyra (omadacycline), alongside steady performance from the PARP inhibitor franchise.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58316\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-27T12:14:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-27T12:14:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58316#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58316\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zai Lab Reports $457M Full\u2011Year Revenue \u2013 16% Growth Driven by Xacduro and Nuzyra Expansion\",\"datePublished\":\"2026-02-27T12:14:23+00:00\",\"dateModified\":\"2026-02-27T12:14:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58316\"},\"wordCount\":387,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finanical Reports\",\"HKG: 9688\",\"NASDAQ:\u202fZLAB\",\"Zai Lab\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58316#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58316\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58316\",\"name\":\"Zai Lab Reports $457M Full\u2011Year Revenue \u2013 16% Growth Driven by Xacduro and Nuzyra Expansion - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-27T12:14:23+00:00\",\"dateModified\":\"2026-02-27T12:14:24+00:00\",\"description\":\"Zai Lab (NASDAQ:\u202fZLAB, HKG:\u202f9688) announced Q4 and full\u2011year 2025 financial results, with net product revenue reaching USD\u202f457.2\u202fmillion (up 16% YoY). The growth was primarily driven by increased sales volumes of Xacduro (durlobactam\\\/sulbactam) and Nuzyra (omadacycline), alongside steady performance from the PARP inhibitor franchise.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58316#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58316\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58316#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zai Lab Reports $457M Full\u2011Year Revenue \u2013 16% Growth Driven by Xacduro and Nuzyra Expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zai Lab Reports $457M Full\u2011Year Revenue \u2013 16% Growth Driven by Xacduro and Nuzyra Expansion - Insight, China&#039;s Pharmaceutical Industry","description":"Zai Lab (NASDAQ:\u202fZLAB, HKG:\u202f9688) announced Q4 and full\u2011year 2025 financial results, with net product revenue reaching USD\u202f457.2\u202fmillion (up 16% YoY). The growth was primarily driven by increased sales volumes of Xacduro (durlobactam\/sulbactam) and Nuzyra (omadacycline), alongside steady performance from the PARP inhibitor franchise.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58316","og_locale":"en_US","og_type":"article","og_title":"Zai Lab Reports $457M Full\u2011Year Revenue \u2013 16% Growth Driven by Xacduro and Nuzyra Expansion","og_description":"Zai Lab (NASDAQ:\u202fZLAB, HKG:\u202f9688) announced Q4 and full\u2011year 2025 financial results, with net product revenue reaching USD\u202f457.2\u202fmillion (up 16% YoY). The growth was primarily driven by increased sales volumes of Xacduro (durlobactam\/sulbactam) and Nuzyra (omadacycline), alongside steady performance from the PARP inhibitor franchise.","og_url":"https:\/\/flcube.com\/?p=58316","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-27T12:14:23+00:00","article_modified_time":"2026-02-27T12:14:24+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58316#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58316"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zai Lab Reports $457M Full\u2011Year Revenue \u2013 16% Growth Driven by Xacduro and Nuzyra Expansion","datePublished":"2026-02-27T12:14:23+00:00","dateModified":"2026-02-27T12:14:24+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58316"},"wordCount":387,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finanical Reports","HKG: 9688","NASDAQ:\u202fZLAB","Zai Lab"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58316#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58316","url":"https:\/\/flcube.com\/?p=58316","name":"Zai Lab Reports $457M Full\u2011Year Revenue \u2013 16% Growth Driven by Xacduro and Nuzyra Expansion - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-27T12:14:23+00:00","dateModified":"2026-02-27T12:14:24+00:00","description":"Zai Lab (NASDAQ:\u202fZLAB, HKG:\u202f9688) announced Q4 and full\u2011year 2025 financial results, with net product revenue reaching USD\u202f457.2\u202fmillion (up 16% YoY). The growth was primarily driven by increased sales volumes of Xacduro (durlobactam\/sulbactam) and Nuzyra (omadacycline), alongside steady performance from the PARP inhibitor franchise.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58316#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58316"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58316#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zai Lab Reports $457M Full\u2011Year Revenue \u2013 16% Growth Driven by Xacduro and Nuzyra Expansion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58316","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58316"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58316\/revisions"}],"predecessor-version":[{"id":58318,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58316\/revisions\/58318"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58316"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58316"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58316"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}